Jianqiang Zhu

Dr. Jianqiang Zhu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YHYue Huang
Yue Huang
DCDapeng Chen
Dapeng Chen
YBYi Bai
Yi Bai
YZYamin Zhang
Yamin Zhang
ZZZhiwen Zheng
Zhiwen Zheng
JZJianqiang Zhu
Jianqiang Zhu
Purpose: Establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2) is involved in the mitotic S-phase adhesins acetylation and is responsible for bridging two sister chromatids. However, present ESCO2 cancer research is limited to a few cancers. No systematic pan-cancer analysis has been conducted to investigate its role in diagnosis, prognosis, and effector function. Methods: We thoroughly examined the ESCO2 carcinogenesis in pan-cancer by combining public databases such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), UALCAN and Tumor Immune Single-cell Hub (TISCH). The analysis includes differential expression analysis, survival analysis, cellular effector function, gene mutation, single cell analysis, and tumor immune cell infiltration. Furthermore, we confirmed ESCO2’s impacts on clear cell renal cell carcinoma (ccRCC) cells’ proliferative and invasive capacities in vitro. Results: In our study, 30 of 33 cancer types exhibited considerably greater levels of ESCO2 expression in tumor tissue using TCGA and GTEx databases, whereas acute myeloid leukemia (LAML) exhibited significantly lower levels. Kaplan-Meier survival analyses in adrenocortical carcinoma (ACC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), mesothelioma (MESO), and pancreatic adenocarcinoma (PAAD) demonstrated that tumor patients with high ESCO2 expression have short survival periods. However, in thymoma (THYM), colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ), ESCO2 was a favorable prognostic factor. Moreover, ESCO2 expression positively correlates with tumor stage and tumor size in several cancers, including LIHC, KIRC, KIRP and LUAD. Function analysis revealed that ESCO2 participates in mitosis, cell cycle, DNA damage repair, and other processes. CDK1 was identified as a downstream gene regulated by ESCO2. Furthermore, ESCO2 might also be implicated in immune cell infiltration. Finally, ESCO2’S knockdown significantly inhibited the A498 and T24 cells’ proliferation, invasion, and migration. Conclusions: In conclusion, ESCO2 is a possible pan-cancer biomarker and oncogene that can reliably predict the prognosis of cancer patients. ESCO2 was also implicated in the cell cycle and proliferation regulation. In a nutshell, ESCO2 is a therapeutically viable and dependable target.

26 April 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JLJingxian Li
Jingxian Li
YQYuanjiong Qi
Yuanjiong Qi
BLBo Li
Bo Li
YLYan Liu
Yan Liu
KYKuo Yang
Kuo Yang
EDE Du
E Du
Background: The primary cilia (PC) is a microtubule-based and nonmotile organelle which protrudes from the surface of almost all mammalian cells. At present, PC has been found to be a deficiency or loss in multiple cancers. Restoring PC could be a novel targeting therapy strategy. Our research showed that PC was reduced in human bladder cancer (BLCA) cells, and PC deficiency promotes cell proliferation. However, the concrete mechanisms remain unknown. SCL/TAL1 interrupting locus (STIL), a PC-related protein, was screened in our previous study and could influence the cell cycle by regulating PC in tumor cells. In this study, we aimed to elucidate the function of STIL for PC to explore the underlying mechanism of PC in BLCA. Methods: Public database analysis, western blot, and enzyme-linked immunosorbent assay (ELISA) were used to screen genes and explore gene expression alteration. Immunofluorescence and western blot were utilized to investigate PC. Wound healing assay, clone formation assay, and CCK-8 assay were used to explore cell migration, growth, and proliferation. The co-immunoprecipitation and western blot were employed to reveal the interaction of STIL and AURKA. Results: We found that high STIL expression is correlated with poor outcomes of BLCA patients. Further analysis revealed that STIL overexpression could inhibit PC formation, activate SHH signaling pathways, and promote cell proliferation. In contrast, STIL-knockdown could promote PC formation, inactivate SHH signaling, and inhibit cell proliferation. Furthermore, we found that the regulatory functions of STIL for PC depend on AURKA. STIL could influence proteasome activity and maintain AURKA stabilization. AURKA-knockdown could reverse PC deficiency caused by STIL overexpression for PC in BLCA cells. We observed that co-knockdown in STIL and AURKA significantly enhanced PC assembly. Conclusion: In summary, our result provides a potential therapy target for BLCA based on the restoration of PC.

12 May 2023 in Environmental Pollution
Verified
Journal Article
Open access
ZZZhiwen Zheng
Zhiwen Zheng
AHAbuduliaizezi Halifu
Abuduliaizezi Halifu
JMJuan Ma
Juan Ma
LLLeyi Liu
Leyi Liu
QFQingfeng Fu
Qingfeng Fu
JZJianqiang Zhu
Jianqiang Zhu
Along with the increasing production and application of graphene oxide (GO), its environmental health and safety (EHS) risks have become a global concern. Numerous studies have investigated the biosafety and toxicity mechanisms associated with GO, however, the majority of previous studies were based on its direct toxic dose, which could not reflect the realistic state of environmental exposure of GO with an indirect toxic dose (low dose). Meanwhile, the effects of low-dose GO on the progression of tumors are still unclearly. Herein, we found that GO can promote multiple types of tumor cell proliferation under its low-dose treatment. Moreover, the lateral size of GO has no obvious distinction on its promoting effect on tumor proliferation. The mechanistic investigation revealed that low-dose GO treatment increased the expression level of integrin αV protein, a cell membrane receptor, and further lead to the constitutively activated PI3K/AKT/mTOR signaling pathway and promoted mitotic progression. Collectively, these findings increased our understanding of the detrimental effects of GO in promoting tumor proliferation, as well as improved our biosafety assessment at its realistic exposure doses.

18 December 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
QFQingfeng Fu
Qingfeng Fu
LSLujie Song
Lujie Song
JLJitao Li
Jitao Li
BYBocun Yi
Bocun Yi
YHYue Huang
Yue Huang
JZJianqiang Zhu
Jianqiang Zhu
Stem cell (SC) therapy has been shown high prospects in erectile dysfunction (ED) treatment. Without ethical issues and risks of immune rejection and tumorigenesis of exogenous SC therapy, endogenous stem/progenitor cells (S/PCs) have a better potential for ED management, and their homing and redistribution are controlled by SDF1-α/CXCR4 axis. Considering black phosphorus nanosheet (BPNS) has emerged as an efficient and safe drug vehicle due to its large surface area, biodegradability, and the ability to retain and slowly release its loaded drugs, BPNS is utilized to load SDF1-α, a chemokine for S/PCs, to construct the BP@SDF1-α complex to efficiently recruit stem cells (SCs) by injury-site injection and thus ameliorate ED within the bilateral cavernous nerve injury (BCNI) rat models. We find that BP@SDF1-α can efficiently recruit exogenous SCs and endogenous S/PCs to corpus cavernosum and main pelvic ganglion (MPG) by local administration. Of note, ascribing to endogenous S/PCs recruitment, it also successfully alleviates ED in BCNI rat models by enhancing the protein expression levels of α-SMA, CD31, and nNOs, and eliciting less collagen deposition in the penis after its combined injection at corpus cavernosum and MPG. Thus, this study provides a new insight into the treatment of ED with endogenous S/PCs. Biodegradable Nano Black Phosphorus based SDF1-α delivery system ameliorates Erectile Dysfunction in a cavernous nerve Injury Rat Model by recruiting endogenous Stem/Progenitor cells

4 July 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
SSShunye Su
Shunye Su
LLLeyi Liu
Leyi Liu
QFQingfeng Fu
Qingfeng Fu
MMMinghao Ma
Minghao Ma
NYNa Yang
Na Yang
JZJianqiang Zhu
Jianqiang Zhu
Background: Prostate cancer (PCa) has a high incidence in men worldwide, and almost all PCa patients progress to the androgen-independent stage which lacks effective treatment measures. PTENP1, a long non-coding RNA, has been shown to suppress tumor growth through the rescuing of PTEN expression via a competitive endogenous RNA (ceRNA) mechanism. However, PTENP1 was limited to be applied in the treatment of PCa for the reason of rapid enzymatic degradation, poor intracellular uptake, and excessively long base sequence to be synthesized. Considering the unique advantages of artificial nanomaterials in drug loading and transport, black phosphorus (BP) nanosheet was employed as a gene-drug carrier in this study. Results: The sequence of PTENP1 was adopted as a template which was randomly divided into four segments with a length of about 1000 nucleotide bases to synthesize four different RNA fragments as gene drugs, and loaded onto polyethyleneimine (PEI)-modified BP nanosheets to construct BP-PEI@RNA delivery platforms. The RNAs could be effectively delivered into PC3 cells by BP-PEI nanosheets and elevating PTEN expression by competitive binding microRNAs (miRNAs) which target PTEN mRNA, ultimately exerting anti-tumor effects. Conclusions: Therefore, this study demonstrated that BP-PEI@RNAs is a promising gene therapeutic platform for PCa treatment. Graphical

1 January 2022 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
JZJianqiang Zhu
Jianqiang Zhu
QFQingfeng Fu
Qingfeng Fu
LSLujie Song
Lujie Song
LLLeyi Liu
Leyi Liu
ZZZhiwen Zheng
Zhiwen Zheng
ZZZhihong Zhang
Zhihong Zhang
Peripheral nerve injury (PNI) is a relatively common disease caused by various circumstances, ultimately affecting the life quality of patients. Although existing medications and surgical interventions have particular benefits for nerve repair, more effective therapeutic strategies are urgently needed for various types of nerve injuries. Increasing investigations of nanomaterials have demonstrated their excellent biological properties, such as biocompatibility, permeability, degradability, high medicine loading efficacy, suitable mechanical properties, and broad applications in the biomedical field. Concerning peripheral nerve (PN) repair, nanomaterials with outstanding biological properties can be fitted as nerve conduits to provide support and guidance for PN regeneration and loaded with functional cells, cytokines, or specific medications to promote regenerative outcomes further. Almost all existing studies have focused on the application of different nanomaterials in PN repair, while the application of nanomaterials in different PN injuries has not been taken into account. This article outlines the application of nanomaterials in the medical field and the prevalent therapeutic strategies for PN repair. Importantly, it focuses on the application of nanomaterials in various PNI diseases, covering injuries of the sciatic nerve, cavernous nerve, facial nerve, median nerve, and more.